XENE - Xenon Pharmaceuticals Inc.

NasdaqGM - NasdaqGM Real Time Price. Currency in USD
7.79
+0.07 (+0.91%)
As of 9:30AM EST. Market open.
Stock chart is not supported by your current browser
Previous Close7.72
Open7.79
Bid7.70 x 900
Ask7.91 x 800
Day's Range7.79 - 7.79
52 Week Range3.60 - 15.92
Volume155
Avg. Volume138,168
Market Cap196.622M
Beta (3Y Monthly)1.78
PE Ratio (TTM)N/A
EPS (TTM)-1.79
Earnings DateMar 5, 2019 - Mar 11, 2019
Forward Dividend & YieldN/A (N/A)
Ex-Dividend DateN/A
1y Target Est16.33
Trade prices are not sourced from all markets
  • GlobeNewswire25 days ago

    Xenon Provides Key Regulatory Updates on XEN007 and XEN1101

    BURNABY, British Columbia, Jan. 28, 2019 (GLOBE NEWSWIRE) --  Xenon Pharmaceuticals Inc. (XENE), a clinical stage biopharmaceutical company, today provided regulatory updates on XEN007 and XEN1101, two therapeutic candidates from its CNS pipeline. The U.S. Food and Drug Administration (FDA) has granted rare pediatric disease (RPD) designation for the treatment of Alternating Hemiplegia of Childhood (AHC) with XEN007 (active ingredient flunarizine).

  • What Kind Of Shareholder Owns Most Xenon Pharmaceuticals Inc. (NASDAQ:XENE) Stock?
    Simply Wall St.last month

    What Kind Of Shareholder Owns Most Xenon Pharmaceuticals Inc. (NASDAQ:XENE) Stock?

    Every investor in Xenon Pharmaceuticals Inc. (NASDAQ:XENE) should be aware of the most powerful shareholder groups. Institutions often own shares in more established companies, while it's not unusual to see Read More...

  • GlobeNewswire2 months ago

    Xenon Pharmaceuticals Outlines 2019 Key Milestones

    Xenon Pharmaceuticals Inc. (XENE), a clinical stage biopharmaceutical company, today provided a corporate update and outlined its anticipated key milestone events in 2019. Dr. Simon Pimstone, Xenon’s Chief Executive Officer, said, “Xenon is entering 2019 in a strong position, poised to support multiple neurology programs that are expected to be in Phase 2 or later stage development this year. With four distinct therapeutic candidates – XEN496, XEN1101, XEN901 and XEN007 – that are aimed at treating neurological disorders, including epilepsy, we intend to pursue a variety of development strategies, such as those focused on using a ‘precision medicine’ approach to address rare pediatric disorders including KCNQ2 epilepsy as well as those targeting broader patient populations, including adult patients with focal epilepsy.

  • Eversept Partners’ Return, AUM, and Holdings
    Insider Monkey2 months ago

    Eversept Partners’ Return, AUM, and Holdings

    Eversept Partners is a New York-based hedge fund that focuses on investing in companies from the healthcare sector. It was founded by its current portfolio manager Mr. Kamran Moghtaderi, who previously worked as an Analyst and Portfolio Manager at Apis Capital Advisors, LLC. Mr. Moghtaderi’s investment experience is much more extensive than this, as prior […]

  • Xenon Pharmaceuticals Inc (XENE): Are Hedge Funds Right About This Stock?
    Insider Monkey2 months ago

    Xenon Pharmaceuticals Inc (XENE): Are Hedge Funds Right About This Stock?

    A whopping number of 13F filings filed with U.S. Securities and Exchange Commission has been processed by Insider Monkey so that individual investors can look at the overall hedge fund sentiment towards the stocks included in their watchlists. These freshly-submitted public filings disclose money managers’ equity positions as of the end of the three-month period […]

  • GlobeNewswire3 months ago

    Xenon Announces Final Results of XEN1101 Phase 1 Clinical Trial and Update on XEN901 Phase 1 Clinical Trial at the American Epilepsy Society (AES) Annual Meeting

    Xenon Pharmaceuticals Inc. (XENE), a clinical stage biopharmaceutical company, today provided clinical updates on XEN1101, a Kv7 potassium channel modulator being developed for the treatment of epilepsy and potentially other neurological disorders and XEN901, a potent, highly selective Nav1.6 sodium channel inhibitor being developed for the treatment of epilepsy. Xenon announced final results from its XEN1101 Phase 1 clinical trial and the related transcranial magnetic stimulation (TMS) studies, along with interim results from its XEN901 Phase 1 clinical trial, in posters at the American Epilepsy Society (AES) Annual Meeting held in New Orleans, LA.

  • GlobeNewswire3 months ago

    Xenon Pharmaceuticals to Host Conference Call and Webcast to Provide Corporate Update and Overview of Presentations at the 2018 American Epilepsy Society (AES) Meeting

    BURNABY, British Columbia, Nov. 30, 2018 -- Xenon Pharmaceuticals Inc. (Nasdaq:XENE), a clinical-stage biopharmaceutical company, today announced that it will host a conference.

  • Thomson Reuters StreetEvents3 months ago

    Edited Transcript of XENE earnings conference call or presentation 6-Nov-18 9:30pm GMT

    Q3 2018 Xenon Pharmaceuticals Inc Earnings Call

  • Granite Point Capital’s Returns, AUM, and Holdings
    Insider Monkey3 months ago

    Granite Point Capital’s Returns, AUM, and Holdings

    Warren Lammert founded Granite Point Capital, a long/short hedge fund with a focus on small-cap companies, in January 2004. The fund is headquartered in Boston, Massachusetts, and Mr. Lammert is its portfolio manager. Prior to launching his own fund, Warren Lammert honed his investment acumen for 14 years at Janus Capital Management LLC as a […]

  • Is Xenon Pharmaceuticals Inc (NASDAQ:XENE) Overpaying Its CEO?
    Simply Wall St.3 months ago

    Is Xenon Pharmaceuticals Inc (NASDAQ:XENE) Overpaying Its CEO?

    Simon Pimstone has been the CEO of Xenon Pharmaceuticals Inc (NASDAQ:XENE) since 2003. First, this article will compare CEO compensation with compensation at similar sized companies. Next, we’ll consider growth Read More...

  • Associated Press4 months ago

    Xenon Pharmaceuticals: 3Q Earnings Snapshot

    The Burnaby, British Columbia-based company said it had a loss of 63 cents per share. Losses, adjusted for non-recurring costs, were 33 cents per share. Xenon Pharmaceuticals shares have more than tripled ...

  • The Zacks Analyst Blog Highlights: Alder, Xenon, Spero and Trevena
    Zacks4 months ago

    The Zacks Analyst Blog Highlights: Alder, Xenon, Spero and Trevena

    The Zacks Analyst Blog Highlights: Alder, Xenon, Spero and Trevena

  • 4 Healthcare Stocks Thriving on Venture Capital Funding
    Zacks4 months ago

    4 Healthcare Stocks Thriving on Venture Capital Funding

    A steady influx of foreign as well as domestic investments in U.S. healthcare has gone a long way in boosting gains for the space.

  • Breakeven On The Horizon For Xenon Pharmaceuticals Inc (NASDAQ:XENE)
    Simply Wall St.5 months ago

    Breakeven On The Horizon For Xenon Pharmaceuticals Inc (NASDAQ:XENE)

    Xenon Pharmaceuticals Inc’s (NASDAQ:XENE): Xenon Pharmaceuticals Inc., a clinical-stage biopharmaceutical company, engages in developing therapeutics to treat patients with neurological disorders in Canada. With the latest financial year loss ofRead More...

  • Benzinga5 months ago

    The Daily Biotech Pulse: Advaxis Posts Narrower Loss, Endocyte Announces $175M Offering, Leadership Transition At Insulet

    Here's a roundup of top developments in the biotech space over the last 24 hours: Scaling The Peaks (Stocks that hit 52-week highs Sept. 7.) Amgen, Inc. (NASDAQ: AMGN )/p BioSpecifics Technologies ...

  • Benzinga6 months ago

    The Daily Biotech Pulse: FDA Blessings for Merck's HIV Drug Combo, Veracyte's Test Gets Medicare Coverage

    Here's a roundup of top developments in the biotech space over the last 24 hours. Scaling the Peaks (Stocks hitting 52-week highs on Aug. 30) Acceleron Pharma Inc (NASDAQ: XLRN ) Avid Bioservices Inc (NASDAQ: ...